MRNA BNT162b Vaccine Elicited Higher Antibody and CD4⁺ T-Cell Responses than Patients with Mild COVID-19.

ABSTRACT: We compared the development and persistence of antibody and T-cell responses elicited by the mRNA BNT162b2 vaccine or SARS-CoV-2 infection. We analysed 37 post-COVID-19 patients (15 with pneumonia and 22 with mild symptoms) and 20 vaccinated subjects. Anti-Spike IgG and neutralising antibodies were higher in vaccinated subjects and in patients with pneumonia than in patients with mild COVID-19, and persisted at higher levels in patients with pneumonia while declining in vaccinated subjects. However, the booster dose restored the initial antibody levels. The proliferative CD4⁺ T-cell response was similar in vaccinated subjects and patients with pneumonia, but was lower in mild COVID-19 patients and persisted in both vaccinated subjects and post-COVID patients. Instead, the prolif

SUBMITTER: Zavaglio F 

PROVIDER: S-EPMC9228401 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature